CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Total revenues	$ 407	$ 153	$ 744	$ 4,317
Operating expenses:
Research and development	21,572	13,557	59,359	38,633
General and administrative	6,531	5,821	20,596	14,247
Intangible asset impairment		3,500		3,500
Gain on fair value remeasurement of contingent consideration	(0)	(1,901)	(6,862)	(1,160)
Litigation settlement related loss			15,000
Total operating expenses	28,103	20,977	88,093	55,220
Operating loss	(27,696)	(20,824)	(87,349)	(50,903)
Investment and other income, net	912	145	1,511	313
Net loss before income tax benefit	(26,784)	(20,679)	(85,838)	(50,590)
Income tax benefit		227		227
Net loss	$ (26,784)	$ (20,452)	$ (85,838)	$ (50,363)
Basic net loss per common share	$ (0.57)	$ (0.45)	$ (1.83)	$ (1.21)
Diluted net loss per common share	$ (0.57)	$ (0.45)	$ (1.83)	$ (1.21)
Shares used in calculating basic net loss per share	46,916	45,453	46,806	41,582
Shares used in calculating diluted net loss per share	46,916	45,453	46,806	41,582
Comprehensive loss:
Net loss	$ (26,784)	$ (20,452)	$ (85,838)	$ (50,363)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	305	(44)	(2,006)	(41)
Comprehensive loss	(26,479)	(20,496)	(87,844)	(50,404)
Product development and licensing agreements
Revenues:
Total revenues			30	29
Contracts and grants
Revenues:
Total revenues	$ 407	$ 153	$ 714	$ 4,288